Skip to main content
. Author manuscript; available in PMC: 2011 Jul 10.
Published in final edited form as: Nat Cell Biol. 2009 Jan 18;11(2):172–182. doi: 10.1038/ncb1831

Figure 2.

Figure 2

CHD8 interacts with and inhibits transactivation by p53. (a) HeLa cells expressing Myc–CHD8S were immunostained with anti-Myc or p53. Scale bar, 5 µm. (b) U2OS cells were incubated with etoposide and then subjected to immunoprecipitation (IP) with an anti-CHD8 antibody, and immunoblot analysis with an anti-p53 antibody. (c) Immunoprecipitation of U2OS lysates with anti-p53 and immunoblot analysis with an anti-CHD8 antibodies. (d) In vitro binding assay for recombinant CHD8S and p53. (e) U2OS cells overexpressing CHD8S were incubated with doxorubicin (DXR) and then subjected to immunoblot analysis with the indicated antibodies. (f) U2OS cells overexpressing CHD8S were treated with the genotoxic agents DXR (0.5 µM) and etoposide (ETOP, 20 µM) and then subjected to qRT–PCR. (g) U2OS cells infected with a retroviral vector encoding CHD8S+L-1 shRNA were subjected to qRT–PCR. (h) Luciferase assay using either wild-type or mutant CHD8SΔ53. Data are mean ± s.d., n = 3 (f–h).